ALEC Alector Inc
Price (delayed)
$1.45
Market cap
$143.67M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.23
Enterprise value
$151.33M
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system
Highlights
The revenue has surged by 63% since the previous quarter and by 3.6% year-on-year
ALEC's gross profit has soared by 63% from the previous quarter and by 3.6% YoY
The equity has increased by 7% QoQ but it has decreased by 5% YoY
The debt has grown by 23% from the previous quarter and by 9% YoY
Key stats
What are the main financial stats of ALEC
Market
Valuations
Earnings
Shares outstanding
99.09M
Market cap
$143.67M
Enterprise value
$151.33M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.12
Price to sales (P/S)
1.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.5
Revenue
$100.56M
Gross profit
$100.56M
Operating income
-$145M
Net income
-$119.05M
EBIT
-$118.92M
EBITDA
-$110.08M
Free cash flow
-$231.16M
Per share
Balance sheet
Liquidity
EPS
-$1.23
EPS diluted
-$1.23
Free cash flow per share
-$2.39
Book value per share
$1.29
Revenue per share
$1.04
TBVPS
$4.85
Total assets
$468.3M
Total liabilities
$341.5M
Debt
$42.52M
Equity
$126.8M
Working capital
$299.76M
Debt to equity
0.34
Current ratio
3.4
Quick ratio
3.32
Net debt/EBITDA
-0.07
Margins
Efficiency
Dividend
EBITDA margin
-109.5%
Gross margin
100%
Net margin
-118.4%
Operating margin
-144.2%
Return on assets
-21.7%
Return on equity
-82.8%
Return on invested capital
-30.4%
Return on capital employed
-34.6%
Return on sales
-118.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALEC stock price
How has the Alector stock price performed over time
Intraday
-3.97%
1 week
-8.23%
1 month
-13.17%
1 year
-76.65%
YTD
-23.28%
QTD
-23.28%
Financial performance
How have Alector's revenue and profit performed over time
Revenue
$100.56M
Gross profit
$100.56M
Operating income
-$145M
Net income
-$119.05M
Gross margin
100%
Net margin
-118.4%
The revenue has surged by 63% since the previous quarter and by 3.6% year-on-year
ALEC's gross profit has soared by 63% from the previous quarter and by 3.6% YoY
The net margin has soared by 54% from the previous quarter and by 12% YoY
ALEC's operating margin has surged by 52% since the previous quarter and by 8% year-on-year
Growth
What is Alector's growth rate over time
Valuation
What is Alector stock price valuation
P/E
N/A
P/B
1.12
P/S
1.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.5
ALEC's EPS is up by 28% from the previous quarter and by 21% YoY
ALEC's P/B is 72% below its 5-year quarterly average of 4.2 and 60% below its last 4 quarters average of 2.9
The equity has increased by 7% QoQ but it has decreased by 5% YoY
The stock's price to sales (P/S) is 94% less than its 5-year quarterly average of 26.0 and 75% less than its last 4 quarters average of 5.8
The revenue has surged by 63% since the previous quarter and by 3.6% year-on-year
Efficiency
How efficient is Alector business performance
ALEC's ROS has soared by 54% from the previous quarter and by 8% YoY
The return on equity has increased by 24% since the previous quarter but it has declined by 7% year-on-year
The return on invested capital has grown by 21% since the previous quarter but it has declined by 12% year-on-year
Alector's ROA has increased by 20% from the previous quarter but it has decreased by 14% YoY
Dividends
What is ALEC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALEC.
Financial health
How did Alector financials performed over time
ALEC's total assets is 37% greater than its total liabilities
ALEC's total liabilities is down by 30% year-on-year and by 14% since the previous quarter
ALEC's total assets is down by 25% year-on-year and by 9% since the previous quarter
The debt is 66% less than the equity
The debt has grown by 23% from the previous quarter and by 9% YoY
The debt to equity is up by 17% since the previous quarter and by 17% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.